Flexion Therapeutics to Present at the Wells Fargo Securities 2019 Healthcare Conference
28 août 2019 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in...
Flexion Therapeutics Reports Second-Quarter 2019 Financial Results and Recent Business Highlights
06 août 2019 16h01 HE
|
Flexion Therapeutics, Inc.
Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $17.0 million in Q2 representing 60% growth over Q1Completed debt financing, which replaces...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 août 2019 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Aug. 02, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to 11 new employees consisting of an aggregate of 68,650 stock...
Flexion Therapeutics to Report Second-Quarter 2019 Financial Results on August 6, 2019
30 juil. 2019 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2019 financial results after the close of the...
Flexion Therapeutics Presents New Data Evaluating Repeat Administration of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Patients with Advanced Knee OA
15 juil. 2019 07h30 HE
|
Flexion Therapeutics, Inc.
An analysis of clinical trial data indicates ZILRETTA reduced pain with similar improvements observed after each of two injections in patients with knee OA classified as Kellgren-Lawrence (KL) Grades...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 juil. 2019 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., July 03, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to ten new employees consisting of an aggregate of 29,050 stock...
Flexion Therapeutics Named one of Boston Business Journal’s Best Places to Work for the Third Consecutive Year
20 juin 2019 09h00 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., June 20, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has been named one of Boston Business Journal’s “Best Places to Work” for the...
Flexion Therapeutics to Present at the BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference
18 juin 2019 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., June 18, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 juin 2019 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., June 07, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to 10 new employees consisting of an aggregate of 25,250 stock...
Flexion Therapeutics Announces Issuance of New U.S. Patent Covering FX201 a Gene Therapy Product Candidate for the Treatment of Osteoarthritis
05 juin 2019 08h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., June 05, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued patent number 10,301,645...